Abstract: Provided herein are compositions comprising ixabepilone, or a pharmaceutically acceptable salt thereof, and a copolymer represented by formula I: Also provided are methods of treating cancer using the compositions described herein, and methods of preparing the compositions.
Abstract: Disclosed, according to one embodiment, is a photodynamic therapy method mediated by a chlorin e6 photosensitizer composite for treating and preventing obesity, the method comprising the steps of: injecting or administering a chlorin e6 composite into a subject; and performing photodynamic therapy on the subject into which the chlorin e6 composite has been injected or administered.
Type:
Application
Filed:
May 15, 2020
Publication date:
October 6, 2022
Applicant:
DONG SUNG PHARM. CO., LTD.
Inventors:
Yong Wan KIM, Mi Young LEE, A Reum RYU, Cheong Wun KIM
Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
Type:
Grant
Filed:
March 16, 2017
Date of Patent:
October 4, 2022
Assignee:
Tillotts Pharm AG
Inventors:
Tea Gunde, Sebastian Meyer, Esther Maria Furrer
Abstract: A method of preparing a protein conjugate contains linking a mono-PEGylated immunoglobulin Fc region to a dual agonist exhibiting activity on both GLP-1 and glucagon. The mono-PEGylated immunoglobulin Fc region is prepared by linking a linker of Formula 1 to the N-terminus of an immunoglobulin Fc region comprising a hinge sequence: CHO-L1-(OCH2CH2)nO-L2-R.
Type:
Application
Filed:
July 18, 2019
Publication date:
September 1, 2022
Applicant:
HANMI PHARM. CO., LTD
Inventors:
Cheongbyeol SHIN, Dooseo JANG, Ji Hye MOON, Dong Hyun KIM, Ji Eun LEE
Abstract: The present invention relates to a method of preparing a suture anchor using a suture and a prepared suture anchor. A knitting member (100) cut at a predetermined width and length while having a plurality of knots (10a) is inserted into a hole 1a of a bone 1 using an anchor inserting device 200, and a second suture 20 provided between one knot 10a of the plurality of knots and another knot 10a thereof is pulled rearwards, and thus the knitting member (100) is deformed from a long rod shape to a lump shape the bone 1. Accordingly, the knitting member (100) has a volume larger than a diameter of the hole 1a, and the knitting member (100) deformed into the lump shape is configured not to be removed from the hole 1a of the bone 1 even when the second suture 20 is further pulled in a rear direction.
Abstract: A urine test device includes a case in which a guide is formed, a strip tray including a strip moving body formed to be slidably movable through the guide, a plurality of strip seating parts formed on the strip moving body, and a strip fixing part configured to fix the strip seated on each of the plurality of strip seating parts, a tray movement driving part configured to slidably move the strip tray, a sensing module supported by the case and including a plurality of light-emitting diodes (LEDs) configured to emit white light for testing toward the plurality of moving strips from above the plurality of strips and a plurality of image sensors configured to detect colors of the plurality of strips, and a control part configured to control the tray movement driving part to move the strip tray.
Abstract: This present invention relates to a drug carrier comprising a polymer of ?-glutamyl transpeptidase catalyzing hydrolysis-induced charge reversal, and a method for preparing the same. It can have a long circulation time in the blood, and can realize a charge reversal from negatively charged or the neutral to positively charged around the tumor blood vessel region, so that the positively charged polymer effectively penetrates deep into the tumor tissue, fast entering into the tumor cells, and greatly improves the therapeutic effect of the drug on the tumor. This overcomes the problems of slow diffusion of traditional polymer drug carriers in tumors and weak interaction with tumor cells, and has great significance in the field of anticancer treatment in the medical field.
Type:
Application
Filed:
May 6, 2022
Publication date:
August 18, 2022
Applicant:
HAINAN POLY PHARM CO., LTD.
Inventors:
Youqing SHEN, Quan ZHOU, Changhuo XU, Jiajia XIANG
Abstract: Provided are a protein conjugate in which a physiologically active polypeptide is linked to a biocompatible material via a non-peptidyl polymer-coupled fatty acid derivative compound serving as a linker, exhibiting an increased duration of physiological activity compared to natural forms and a preparation method therefor. Since an increase in serum half-life of the physiologically active polypeptide of the protein conjugate, in which the biocompatible material, the non-peptidyl polymer-coupled fatty acid derivative compound, and the physiologically active polypeptide are linked, is proved, the protein conjugate may be widely used in the field of protein drugs.
Type:
Application
Filed:
May 6, 2022
Publication date:
August 18, 2022
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Su Yeon PARK, Ji Young SONG, Eun Jung KIM, Jong Min LEE, Jong-Soo LEE, Dae Jin KIM
Abstract: The present invention relates to a drop-forming, storage stable, multiphase, ophthalmic composition comprising at least one liquid aqueous phase and at least one liquid hydrophobic phase, characterized in that it is emulsifier-free as well as buffer-free and comprises hyaluronic acid and/or hyaluronate.
Type:
Grant
Filed:
April 12, 2017
Date of Patent:
August 16, 2022
Assignee:
DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH
Abstract: A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.
Type:
Application
Filed:
April 14, 2022
Publication date:
August 11, 2022
Applicant:
HANMI PHARM. CO., LTD.
Inventors:
Jaehyuk Choi, Min Young Kim, In Young Choi, Sung Youb Jung
Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.
Type:
Application
Filed:
April 27, 2022
Publication date:
August 11, 2022
Applicant:
HANMI PHARM. CO., LTD
Inventors:
Dae Jin KIM, Jong Soo LEE, Young Jin PARK, Sung Hee HONG, Sung Min BAE, Se Chang KWON
Abstract: A triptolide derivative, a preparation method therefor, and a method for use thereof are described. The triptolide derivative has the structure as shown in general formula I, and the definition of each substituent is as described in the description and claims. The triptolide derivative has improved immunosuppressive activity and anti-tumor activity, low toxicity and high safety, thus having good development and application prospects.
Abstract: Provided is a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof; a pharmaceutical composition for the prevention or treatment of Sirt6-associated diseases, including as an active ingredient, a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof; and a method for treating Sirt6-associated diseases including administering a phthalazinone compound, or a racemate, steroisomer or pharmaceutically acceptable salt thereof to a subject in need.
Type:
Application
Filed:
May 29, 2020
Publication date:
July 28, 2022
Applicants:
ST PHARM CO., LTD., KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
Inventors:
Kyungjin KIM, Kwangrok KIM, Uk-Il KIM, Hyung Tae BANG, Seul Ki LEE, Kwan-Young JEONG, Seung Kyu KANG, Heejung JUNG, Sang Dal RHEE, Won Hoon JUNG, Jun Mi LEE
Abstract: A method for preparing dihydroartemisinin bulk drug in single process comprises: S1. dissolving artemisinin in aprotic solvent; S2. adding phase transfer catalyst and reducing agent in sequence to cause a reduction reaction with artemisinin; S3. adjusting the pH of the reaction system obtained in step S2 to 5-7 with acid solution, adding water and stirring, separating the liquids, extracting the aqueous phase obtained by the separation with the same aprotic solvent as in step S1, combining the organic phase obtained by extraction and separation, washing with water, and drying, obtaining dried organic phase; S4. placing the dried organic phase obtained in step S3 in a crystallization device that has the functions of crystallization-press filtration-drying, and then the crystals are precipitated, concentrated, press-filtered, and dried to obtain the refined dihydroartemisinin.
Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex prepared by the present invention may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.
Type:
Grant
Filed:
September 26, 2016
Date of Patent:
July 19, 2022
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Dae Jin Kim, Jong Soo Lee, Young Jin Park, Sung Hee Hong, Sung Min Bae, Se Chang Kwon
Abstract: The present invention relates to a pharmaceutical composition for treating and/or alleviating a psychiatric disorder comprising a sulfamate derivative compound and/or a pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the present invention relates to a pharmaceutical composition for inducing anti-stress, anti-anxiety and/or anti-depressant activities comprising a sulfamate derivative compound and/or a pharmaceutically acceptable salt thereof as an active ingredient.
Abstract: Provided is, as an attempt to realize a method for measuring oxidative stress in human body fluids, a means for measuring reactive oxygen species containing a color indicator that detects the amount of reactive oxygen species present in the human body by causing a color change through reaction with malondialdehyde present in the urine or blood. The detection means has advantages of detecting malondialdehyde (MDA) present at a low concentration in a sample (urine or blood) and exhibiting excellent discrimination owing to high detection sensitivity.
Type:
Grant
Filed:
May 11, 2018
Date of Patent:
July 12, 2022
Assignee:
CHUNGDO PHARM. CO., LTD
Inventors:
Sung-Jin Kim, Sung-Jae Lee, Abeje Abebayehu Silte